The authors go on to demonstrate that canonical ALT cells, likely due to their lack of functional ATRX, are equally sensitive to PolI inhibitors, suggesting that PolI inhibitors could be effective on a wide range of ALT cancers (52). This evidence concerns the gene ATRX and cancer.